Arcellx, Inc.
arcellx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2025 10-K, filed Feb 26, 2026. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2026.
10-K for FY2025, filed Feb 26, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops engineered immune-cell treatments for people with cancer and autoimmune diseases, including multiple myeloma and leukemia.
10-K for FY2025, filed Feb 26, 2026
How Did They Make Money?
Kite pays Arcellx upfront and may pay clinical, regulatory, and commercial milestones; for development work, Arcellx earns revenue as third-party costs are incurred against budget. Commercialized products can also bring shared U.S. profits or royalties.
10-K for FY2025, filed Feb 26, 2026In connection with the initial Kite Collaboration Agreement, we received a $225 million upfront cash payment in February 2023 and will be…View ↗
As described in Notes 2 and 8 to the consolidated financial statements, the Company’s consolidated revenue was $22.3 million for the year…View ↗
In the United States, we and Kite will equally share profits and losses from the commercialization of the anito-cel and any next-generation…View ↗
$22.3M
-
10-K for FY2025, filed Feb 26, 2026
$22.3M ↗
Did Revenues Turn Into Profits?
No. It lost $228.9M in FY2025.
10-K for FY2025, filed Feb 26, 2026
−$253.1MView ↗
10-K for FY2025, filed Feb 26, 2026
−$228.9MView ↗
10-K for FY2025, filed Feb 26, 2026
−$212.6MView ↗
How Were They Changing?
-
Apr 28, 2026
The tender offer and merger closed
Arcellx became a wholly owned subsidiary after the merger.
Sources
8-K, filed Apr 28, 2026
The Offer expired at 5:00 p.m., Eastern Time, on April 27, 2026 (the “Expiration Time”). According to Computershare Trust, the depositary…View ↗
Autoimmune development
The older report described autoimmune disease as a potential area; the latest report says Arcellx began a clinical trial of anito-cel for generalized myasthenia gravis.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients…View ↗
Outside our collaboration with Kite, we are also advancing anito-cel into select autoimmune disorders. In the second half of 2025, we began…View ↗
Who Did They Compete With?
Competes with AbbVie, Allogene, Amgen, AstraZeneca, Autolus, Bristol Myers Squibb, Cabaletta, Caribou Biosciences, CARsgen, Cartesian, Cellectis, Cellular Biomedicine Group, Celyad, Crispr, Gilead, GSK, Immix, Innovent, Johnson & Johnson, and Kelonia
10-K for FY2025, filed Feb 26, 2026We anticipate substantial direct competition from other organizations developing advanced CAR-Ts, other types of genetically modified cell…View ↗
Loading...
